EP1148936B1 - Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures - Google Patents

Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures Download PDF

Info

Publication number
EP1148936B1
EP1148936B1 EP00983840A EP00983840A EP1148936B1 EP 1148936 B1 EP1148936 B1 EP 1148936B1 EP 00983840 A EP00983840 A EP 00983840A EP 00983840 A EP00983840 A EP 00983840A EP 1148936 B1 EP1148936 B1 EP 1148936B1
Authority
EP
European Patent Office
Prior art keywords
admixture
prescription
components
compounder
compatibility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00983840A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1148936A1 (en
Inventor
Joseph J. Kircher
Ronald W. Czarny
Robert E. Lewis
Diane M. Nitzki-George
Joseph E. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Priority to EP06075077.5A priority Critical patent/EP1656988B2/en
Publication of EP1148936A1 publication Critical patent/EP1148936A1/en
Application granted granted Critical
Publication of EP1148936B1 publication Critical patent/EP1148936B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/80—Mixing plants; Combinations of mixers
    • B01F33/84—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/80—Mixing plants; Combinations of mixers
    • B01F33/84—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins
    • B01F33/844—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins with means for customizing the mixture on the point of sale, e.g. by sensing, receiving or analysing information about the characteristics of the mixture to be made
    • B01F33/8442—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins with means for customizing the mixture on the point of sale, e.g. by sensing, receiving or analysing information about the characteristics of the mixture to be made using a computer for controlling information and converting it in a formula and a set of operation instructions, e.g. on the point of sale
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/80—Mixing plants; Combinations of mixers
    • B01F33/84—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins
    • B01F33/848—Mixing plants with mixing receptacles receiving material dispensed from several component receptacles, e.g. paint tins using data, i.e. barcodes, 3D codes or similar type of tagging information, as instruction or identification codes for controlling the dispensing and mixing operations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/80—Forming a predetermined ratio of the substances to be mixed
    • B01F35/83—Forming a predetermined ratio of the substances to be mixed by controlling the ratio of two or more flows, e.g. using flow sensing or flow controlling devices
    • B01F35/832—Flow control by weighing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/70—Device provided with specific sensor or indicating means
    • A61J2200/74—Device provided with specific sensor or indicating means for weight
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions

Definitions

  • the present invention generally relates to a method and apparatus for preparing and accounting for pharmaceutical admixtures. More particularly, it relates to strategies for preparing prescriptions for parenteral admixtures, for controlling the compounding apparatus, and for properly accounting for the prepared admixture with the strategies being implemented in computer software.
  • parenteral admixtures are a combination of sterile drugs that are mixed together under aseptic conditions and are intended for intravenous infusion. These admixtures may be relatively simple or extremely complex, with the complexity increasing with the inclusion of multiple active ingredients.
  • Nutrition admixtures are one example of complex parenteral admixtures that are frequently prepared in a hospital pharmacy for treating patients in the hospital.
  • parenteral nutrition admixtures (PN) refer to most types of nutritional solutions for intravenous feeding.
  • TPN total patenteral nutrition admixtures
  • TPN total patenteral nutrition admixtures
  • TAA total nutritional admixtures
  • the pharmacy of a hospital, a compounding center or a care facility prepares or compounds a prescription which typically has been determined by a physician singularly or in conjunction with a dietician, pharmacist or other care provider.
  • the pharmacy may be required to compound large numbers of PN on a daily basis.
  • the actual PN compounding is done primarily by electomechanical mixing equipment called compounders which are extremely sophisticated and are adapted to admix many different components in differing proportions as set forth in pharmaceutical prescriptions.
  • Compounders include high volume compounders which are adapted to prepare PN by transferring those components which are normally found in relatively large volumes in a PN, for example amino acids, sterile water, lipids and dextrose, at a relatively high speed.
  • Such compounders include the AUTOMIX 3 + 3 compounder manufactured by the Clintec Nutrition Division of Baxter Healthcare Corporation.
  • Compounders also include low volume compounders such as compounders from the same corporation marketed as a MICROMIX compounder.
  • the MICROMIX compounder is adapted to accurately transfer those components that are normally found in relatively small volumes in a PN.
  • pharmacies to produce a prescribed PN by utilizing both a MICROMIX and an AUTOMIX compounder, typically by adding the high volume components to the final container or final bag with the AUTOMIX compounder and then transferring the final bag to the MICROMIX compounder for transferring the smaller volume components.
  • a single compounder may have the capability of transferring both high volume components and low volume components either sequentially or concurrently.
  • the single compounder could have both a high volume module and a low volume module that could transfer fluid to a common manifold, a common transfer tube connected to a final bag or container, or into separate ports in a final bag.
  • the pharmacist In preparing the proper prescription for a particular patient the pharmacist must perform many tasks including evaluation and determination of the proper components and their respective amounts. Patient specific factors including the type of patient i.e. neonatal, and weight of patient, will be considered. Improving the ability of the pharmacist in making such evaluations and determinations will increase the throughput and reduce the possibility of errors. For record keeping purposes it is desirable and on occasion required for the pharmacist to note in a permanent record why the prescription differs from generally desired amounts of source solutions.
  • Compatibility is defined as the interaction between a drug and all other components with which that drug comes into contact, including but not limited to the diluent, the container and other drugs in the same PN.
  • Compatibility is divided into two subcategories which are physical as well as chemical compatibility.
  • Physical compatibility is defined as an incompatibility that will alter the physical appearance of the drug, typically resulting in a visual change such as precipitation, gas evolution or a change in color. Chemical incompatibilities are not visually observed but must be analytically tested.
  • compatibility of the entire PN over the period between preparation of the admixture and completion of delivery to the patient should be evaluated prior to compounding.
  • the compounding preparation process must be planned in a way to allow for compatibility while the compounding process is proceeding. For example, the compatibility between a source solution being added to the final mixing container or any intermediate mixing container and the solution present in that container should be evaluated. In many instances source solutions which are packaged at concentrations which are incompatible with other solutions must be diluted before they come into contact with each other in such chambers.
  • the highest dilution will occur when the greatest amount of diluting fluids are already present in the container into which the solutions are being added.
  • amino acid or dextrose source solutions will form a large portion of a PN and yet are typically compatible with most additives. Thus it would seem that these solutions would be transferred first to the final container or to any intermediate mixing chambers to dilute added source solutions.
  • One method to reduce the possibility of a solution being incompatible with a second solution along a common flow path is to flush the common flow path after each solution has been transferred. Such flushing is accomplished with a solution which is compatible with both the prior solution as well as the solution to be added after the flush. As can be appreciated frequent flushing dilutes the incompatible solutions thereby making them compatible but will also decrease throughput.
  • the source of such flushing solutions may either be a compatible source solution which forms a part of the prescription or the solution present in a downstream chamber such as an admixture in the final mixing container.
  • the prescribed amount of solutions which are used as flushing solutions are typically transferred first to the final container for expediency and dilution purposes and are not available as flushing solutions.
  • the solution in the final bag must be compatible with the solution which is to be flushed, and the flushing solution will be drawn from the final container. Drawing the flush from the final bag and returning the flush to the final bag decreases throughput.
  • holding back an amount of the diluting source solutions for flushing may lead to instances where two incompatible solutions come into contact with each other in the final mixing chamber without being properly diluted to a compatible concentration.
  • a pharmacist will typically group solution containers in dependence on the operating scheme of the compounder so that ingredients which are compatible with each other (at source solution concentration) are added together sequentially between rinses which are set by the pharmacist. After making a determination regarding the compatibility of the various solutions the pharmacist may group a set of compatible solutions on station 1-4, a second set of compatible of compatible solutions on stations 5-8, etc with rinses set after station 4, station 8, etc. However, a particular admixture may require 5 solutions which are compatible. Because setting rinses requires greater time and effort, the pharmacist may hang the fifth ingredient at a station which has rinses before and after rather than adjust the station arrangement and rinsing scheme. This however is not optimal.
  • lipid hazing in which a trace of lipid is present in a final solution which is not to contain lipids. Hazing can be produced by lipids being present in amounts as low as one to 3 parts per million. Such hazing will typically occur when a prescription containing lipids is compounded immediately prior to a prescription which is not to contain lipids. Lipid hazing is not generally believed to create a health hazard, however lipid hazing in a PN which is to be infused may be later mistaken for a PN with unacceptable precipitation arising from an error in formulating a compatible PN solution, and the hazy solution may be mistakenly discarded.
  • lipid hazing is an issue the pharmacist may seek to avoid such problems by flushing the compounder after each prescription containing lipids is compounded. However, such flushing will decrease throughput and not be totally effective. To increase throughput, the pharmacist may decrease such flushing by grouping lipid prescriptions; however such groupings have a negative impact on flexibility. If lipid hazing is not an issue, the possibility of lipid hazing should be communicated to persons who are compounding the solution and who are administrating the PN to the patient to prevent the administer from mistakenly believing that the admixture has become unstable.
  • the prepared admixture For reimbursement and record keeping purposes, the prepared admixture must be accounted for which is generally accomplished by reporting either manually or electronically transferring information into a facility's accounting system. The steps the pharmacist must perform to insure that an admixture is properly accounted for should be minimized to increase efficiency.
  • a related object of the present invention lies in the provision for selectively determining the order or reorder of a plurality of admixture solutions or compatibility groups that may reside in a prescription, to more efficiently prepare the prescriptions, such as by maximizing the number of prescriptions which may be prepared over a set time period.
  • a more detailed object of the present invention is to provide such an improved method and apparatus for controlling a compounder of the type which utilizes an intermediate mixing chamber such as a funnel for admixing components prior to transferring the contents of the chamber to the final mixing chamber such as a final bag.
  • Another object of the present invention lies in the provision of patient specific data to enhance the ability of the pharmacist to efficiently formulate and safely compound admixtures from prescriptions.
  • Still another object of the present invention is to provide an improved method and apparatus for allowing the pharmacist to efficiently compensate for the accuracy limits of the compounder and inefficiencies in administering the PN to the patient such as the fluid which is lost in the administration sets.
  • Yet another object of the present invention is to provide an improved method and apparatus which includes a higher concentration formulation of an ingredient to be substituted for a prescribed formulation but determines whether the diluting fluid may be provided by compatible other ingredients so that the volume of the resultant admixture is minimized.
  • Another object of the present invention is to provide such an improved method and apparatus which controls the compounding to alert users when recommended limits are not being adhered to and such alerts are not accidentally ignored.
  • a related object is to provide for the input and recording of the rationale in overriding a warning.
  • Another object of the present invention is to provide a method and apparatus which reduces instances or alerts users to the possibility of lipid hazing and the possibility that such lipid hazing will be accidentally mistaken for an unacceptable precipitate.
  • the present invention provides an apparatus for use in controlling the operation of at least one pharmaceutical compounder according to claim 1 and a method of controlling the operation of at least one pharmaceutical compounder according to claim 24.
  • the present invention is directed to a method and apparatus for controlling the compounding of pharmaceutical admixtures, where the compounding is done by one or more compounders that may be remotely located relative to the controller computer or processing means that is interconnected with the compounders.
  • the controller computer or controller 10 has sufficient memory for storing pharmaceutical data in the form of a database as well as operating software for use in controlling compounders and other peripheral equipment.
  • the computer 10 is preferably a multi-user, multi-tasking computer that has a communication interface for interconnecting to compounders 12, 14 and 16 and other peripheral equipment such as printers 18 and 20 by communication links 22 that may be wired or wireless, may be part of a local area network, a wide area network or the Internet or a combination of the above.
  • the computer 10 may have a display 23 and keyboard 25 as well as other accessories and features common to commercially available computers at this time.
  • Other peripheral equipment can include a dumb terminal 24 having a keyboard and display or other input device such as a laptop computer 26 or other handheld device that is adapted to enter prescriptions and input instructions for operating the controller computer software.
  • the compounders may be located in different areas of a healthcare facility such as a hospital, or on different floors of a hospital or even at different hospitals.
  • the compounders 12 and 14 as well as the printer 18 and terminal 24 are located in hospital B in FIG. 1, whereas the remainder of the equipment is shown to be located in hospital A.
  • the controller computer 10 is preferably interconnected with a general hospital computer 28 that may be used to prepare and record billing statements among other functions.
  • the present invention is adapted to control compounders such as compounders 12, 14 and 16.
  • the presence of two machines in hospital B is to indicate that two different types of compounders may be used in combination to prepare prescription admixtures, such as by but one example, the aforementioned AUTOMIX and MICROMIX compounders.
  • the compounders 12 may be a compounder adapted for transfer of high volume additives and the compounder 14 may be a compounder adapted for low volume additives.
  • the compounder 16 may be adapted to transfer both high volume and low volume amounts of ingredients.
  • a perspective view of a low-flow module compounder is illustrated and is adapted to transfer small volumes of components such as micro-nutrients and other drugs from individual source containers 30.
  • prescription admixtures may be prepared by a single compounder 16 adapted to transfer high volume and low volume additives or multiple compounders attached to a single final bag 46.
  • the fluids from the containers 30 is transferred through a separate individual fluid conduit 32 to a single intermediate container or funnel 34 that is suspended from a load cell assembly 36.
  • the load cell assembly 36 weighs the total weight of the funnel 34 to develop an output signal, which is indicative of the amount of fluid in the funnel 36 at any given time.
  • the funnel 34 is closed and is connected to a pressure conduit 38 that is connected to a pressure means and occlusion means such as a valve 40 by example.
  • the pressure means is preferably a single peristaltic pump which can selectively create positive and negative pressures in the funnel 34 to control the direction and flow of fluid into and out of the funnel 34.
  • the funnel 34 also is connected to an outlet conduit 42 that extends to a second occlusion means 44 that is interposed between the funnel 34 and the final bag or container 46.
  • a second occlusion means 44 that is interposed between the funnel 34 and the final bag or container 46.
  • the compounder 12 may also include an assembly that transfers the additives utilizing other methods of operation such as one or more pumping mechanisms and switching mechanism alone or in combination with volumetric delivery methods, possibly including calibration such as the compounding devices supplied commercially by the BAXA Corporation of Englewood, Colorado.
  • FIG. 3a further embodiment of compounder 50 is represented which is particularly suited for transferring large volume additives.
  • the compounder 50 includes a number of individual pumping stations 52 which cooperate with a disposable transfer set 54 to pump fluids from individual source containers 56 to a final container 58.
  • a detailed operation of an example of a compounder adapted to transfer low volume components, at least as of approximately 1999 is described in US Patent Nos. 4,712,590 and 5,927,349 which is assigned to the same assignee as the present invention.
  • the current commercial AUTOMIX compounder may embody certain improvements compared to the '485 and '349 patents, but is believed to be similar to that described in the patent.
  • a physician or other healthcare provider or group of providers determine what is the parenteral nutritional needs of a patient and arrive at a prescription.
  • a pharmacist will then need to convert the prescription into particular amounts or concentration of additives in the PN which is to be administered to the patient. These amounts will vary in dependence on the particular patient. For example the patient may not be able to accept a large amount of fluid parenterally and, the nutritional needs will need to be accomplished within a minimal amount of fluid.
  • a fluid restricted patient is a neonatal patient.
  • the level of concentration of the additive in the final bag 46 may be higher in the PN than if more of a diluent volume could be used. This higher concentration may lead to a greater chance of compatibility problems with other additives in the PN and may exceed acceptable limits for that patient.
  • the pharmacist enters patient identifying data such as a patient ID code into the controller utilizing the keyboard 25 (block 70).
  • the controller 10 requests and accepts patient specific data (block 72) from a data storage location such as the computer system 28 of the facility and displays such information on the display 23.
  • patient specific data which is preferably utilized by the controller 10 in the preferred embodiment is the patient type such as premature, neonatal, pediatric or adult, etc.
  • the provider enters the patient specific data directly into the controller 10 or a storage location therein.
  • the controller 10 also retains in a storage location preferred ranges for the acceptable concentration levels of the different admixtures in a final bag 46.
  • the controller 10 may also retain in the data storage location, concentration ranges for the ingredients for the various patient types and set the preferred concentration range with a type dependent range for that particular patient.
  • ranges corresponding to patient attributes such as various patient ages and weights may be retained in the data storage location and the controller 10 may set the preferred concentration range with attribute specific ranges.
  • the controller may also contain an algorithm for adjusting the concentration range in dependence on predetermined patient specific factors such as the age of the patient.
  • the controller 10 may evaluate whether the preferred ranges are appropriate for the patient specific type and may then adjusts the range (block 74).
  • the health care provider will then enter the prescription (block 76) by, for example, utilizing the keyboard 25.
  • the provider will set concentration levels of the ingredient solutions so that upon compounding the PN will correspond to the prescription.
  • the controller 10 allows the prescription to be entered in several different formats. By way of example the controller 10 may accept inputs of the ingredients in percent of the final solution, concentration per unit volume or an amount corresponding to the per unit weight of the patient.
  • the controller 10 checks the entered concentrations against the determined ranges (block 78). If a concentration is entered which is outside the range, an error message is displayed on the display 23. In addition, if the provider enters an ingredient with an inappropriate format an error or alarm message is displayed on the display to alert the health care provider.
  • An example of an inappropriate format is where the concentration is entered in units of measure per the patients weight but the patients weight has not been input as part of the patent specific data.
  • controller 10 may then review the various ingredients and highlight with error messages those ingredients which fall outside the range which has been set for that ingredient.
  • templates of various prescriptions corresponding to various patient types may be retained in a storage location.
  • the pharmacist or controller 10 may then call up the template and either accept or adjust the template.
  • a previous prescription of the patient may be retained in a storage location.
  • the pharmacist or controller 10 may then call up the prior prescription and either adjust or accept the prior prescription to be utilized as the present prescription.
  • the controller 10 may then in certain predetermined instances allow the provider to override the alarm (block 82).
  • the controller 10 will allow an override upon the occurrence of one or a combination of certain factors. One factor is whether the provider entering the prescription has the clearance to override the particular alarm. An each alarm may require a different level of clearance before the override is accepted. Some alarms may not be overridden.
  • the identity and clearance level of the provider may be established by a unique password that is requested by the controller 10 and entered at an appropriate time such as at the beginning of the entry of the prescription or at the occurrence of an alarm (block 84).
  • Other methods of establishing the identity of the provider are also contemplated such as keycards, retina scans or the like.
  • the controller 10 may require that the rationale for the override be entered into a note screen displayed on the display 23. For certain alarm situations, the controller 10 does not allow any overrides even with a rationale (block 86).
  • the preferred embodiment of the present invention evaluates the compatibilies of the ingredients and the solutions into which the ingredient comes into contact during the compounding process and also the solution in the final solution bag 46 after the compounding is complete.
  • the evaluation of the final prepared PN is a process that is routinely performed by pharmacists.
  • the pharmacists compare the components of the final prepared admixture to literature, which has information concerning compatibility.
  • the literature is not sufficiently specific to the exact type of ingredients in the admixture being prepared, which requires the pharmacist to use professional judgment in deciding whether the resulting admixture will be compatible.
  • the overall compatibility evaluation for complex admixtures primarily focuses on the compounding of parenteral nutrition, which broadly includes PN screening and calcium phosphate solubility screening.
  • the process preferably involves a first screening step of comparing all PN additives to limits set by the controller 10 which may include the steps of setting ranges preferred concentration limits as described above
  • a second step involves comparing the final concentration of amino acids, dextrose and lipid based components to the database of tested admixtures.
  • Amino acid comparisons are brand specific.
  • Databases of admixtures have been compiled through the testing of admixtures and also by utilizing published literature.
  • the admixture database preferably comprises concentrations for both stable and unstable admixtures with a notation of the study conditions such as time and temperature.
  • the database includes admixtures having identified source components such as by example, brand named amino acids.
  • the prescribed admixture is compared to the database of admixtures.
  • the comparison is first carried out against admixtures having identified source components. If the prescribed admixture falls within some range of a stable admixture the present invention proceeds to the next step without generating a notice to pharmacists.
  • the range may be set by some variance amount, for example by a set percent of the amounts or concentration levels of corresponding base components in a stable admixture.
  • admixtures with matches (or mixed stable and unstable matches) to the unstable formulation contained in the database may be designated as potentially unstable.
  • a further step may be performed such as screening whether the study conditions of the matched admixture are equivalent to the present conditions.
  • the present invention provides a warning to pharmacists that the admixture is equivalent to potentially unstable admixture under the study conditions of that admixture.
  • admixtures that do not match any stable or unstable admixtures contained in the database are re-evaluated.
  • the amino acid brand is ignored and the admixture is then compared to the entire database.
  • the results of this comparison are handled following the same steps that have been previously described.
  • the pharmacist would be provided a warning about the ignoring of the amino acid brand of the database admixture. If the admixture does not match the database after re-evaluation of the entire database, the present invention will provide a warning notice to the pharmacist that no similar PN has been previously tested.
  • solubility of calcium salts and phosphate salts in the same solution is dependent on many variables including, but unlimited to concentration, temperature, salt form, order of mixing, pH, amino acids concentration, other additives and time. It has been the practice in the prior art for the pharmacist to compare the final concentration of both the calcium salt and phosphate salt to a solubility curve that is specific to a given amino acids brand and final concentration.
  • the calcium phosphate solubility screening in a complex compounding process is achieved by the controller 10 comparing the final concentration of both the calcium salt and phosphate salt to a matrix of known compatibility.
  • the matrix may be input into a storage location by the Pharmacist or previously input into the database
  • the present invention uses the matrix to sort compatibility by the amino acids brand and final concentration.
  • a calcium phosphate solubility matrix for a specific amino acids brand may have compatible concentrations of calcium salts and phosphate salts for a 1%, 2% and 4% final amino acid concentration.
  • the present invention determines the limits of solubility that have been exceeded and will generate a warning to the pharmacist if it has.
  • the controller 10 may generate and display on the display 25 a graph of a shape representing the calcium phosphate solubility for that a particular amino acid and may also present a designation of the prescribed admixture relative to the solubility shape to assist the pharmacist in achieving a prescription which is compatible.
  • compatibility during the compounding process must be evaluated. For example, the compatibilities of a solution with a second solution at the time of contact must be evaluated.
  • the second fluid may be found in a common conduit, intermediate mixing chamber or final bag.
  • the pharmacist may adopt gross rules for the compounding process. For example it is common practice that all diluent volumes are added to the final bag first so that all additives which are present in the final bag are diluted as much as possible at the time of the addition of an additional ingredient to the final bag. However, such a practice reduces the ability to rinse from such a diluent during the compounding process.
  • the controller computer 10 may utilize the known compatibilities of components to enable concurrent compounding of such compatible components into the final bag or an intermediate mixing chamber.
  • rinsing may be accomplished with a source solution which is compatible with both the solutions flowing through the rinsed portion before and after the rinsing.
  • large volume additives may be transferred to the final container or bag or transferred to an intermediate mixing chamber at the same time as small volume additives or used as rinsing fluids.
  • compatibility screening and concurrent compounding enables the present invention to maximize the speed in which admixtures are compounded which results in more efficient use of the compounders, as well as the controller computer.
  • testing of components for compatibility characteristics is used to build a database that includes a plurality of groups, which represent concentration dependent compatibility on the basis of testing of components.
  • groups which represent concentration dependent compatibility on the basis of testing of components.
  • the compatibility groups may be known based on test results and are contained in the database of the controller computer so that the compounding process can be carried out with the information in the database. It is preferred that the database be located only in the controller computer, rather than be distributed to various locations so that it can be reliably controlled, managed and modified as additional knowledge and information is gained through history, continued testing, and the addition of other drugs and components to the database.
  • the controller will logically group the fluids in the source containers 30 (Fig. 2) into the compatibility groups regardless of their physical placement on one of the compounder 12, 14, 16.
  • the controller shall calculate for a particular prescription, the number of groups present and the sorting of the groups into sets of compatibility groups between which a rinse is required such that the total number of rinses is minimized.
  • the controller utilizes other inputs such as physical restraints of the system to determine the proper compounding sequence to more efficiently utilize source solutions as rinses as opposed to rinses from the final bag.
  • physical restraints may include the volume of an intermediate chamber or funnel 34 and the rinse volume for such a chamber.
  • the intermediate chamber has a funnel with a volume of 60 ml and a rinse volume requirement of 30 ml. If the prescription calls for 5 ml of Group 1, 20 ml of Group 2; 20 ml of Group 3; 55 ml of Group 4 and 40 ml of Group 6, the controller 10 may adopt a compounding order of Group 1, Group 2, Group 3, Group 6 and Group 4 instead of ascending sequence.
  • sorting relationships or algorithms may be defined and implemented by the controller to accomplish the desires of the users, such as allocating the volume of a group to other compatible groups to reduce the number of draining of the chamber or funnel 34 may be minimized.
  • the database may be considered to be proprietary as its sophistication increases and control of the database at a single location is a significant protection that would not be present if the database were to be distributed to a processor in each compounder, for example.
  • FIGS. 4b-4h illustrates the preferred embodiment of a method of defining the operation of at least one compounder to provide a nutritional formula admixture.
  • the start (block 100) of the method or process is shown in FIG. 4b and occurs after prescriptions have been entered into the controller computer.
  • the prescription are initially screened by the controller 10 in one or more of the methods described above.
  • the next step is to decide the compounding strategy (block 102) which is in part dependent upon the kind of compounding equipment that is present.
  • a hospital, other healthcare facility or pharmacy may have only a high-flow module compounder 12 (Fig. 1) which is adapted to transfer high volume fluids at a relatively high flow rate.
  • a high-flow module compounder 12 Fig. 1
  • the controller decides compounding strategy (block 2) determines which strategy to employ.
  • the program is adapted to control either a high flow rate (block 104) which would control a high-flow module compounder for example, a low flow rate (block 106) which would control a Low-flow module compounder, for example, or a high and low flow rate (block 108) which would result in both machines being used or for a single compounder 16 suitable for both high volume and low volume transfers, for example.
  • the controller performs initial compounder calculations for high flow only compounder set up (block 104) which comprises several calculations that the program will execute for each large volume component that will be part of the final bag. This includes the calculation based on specific gravity to convert volume measure to weight measure, if the transfer is carried out by utilizing the weight of a component that is transferred rather than volume that is transferred.
  • a prescription may be written using measurements that are input by grams or milliliters or a percentage of the final solution and the software may be required to convert the measurements to weight, if the compounders transfers in dependence on the sensed weight of the transferred component.
  • the high-flow module 14 and low-flow module compounders 12 compound utilizing the weight or change of weight of an intermediate or final container.
  • line 110 extends to FIG. 4c where a determination is made whether a prescription containing lipids should have the lipids transferred to the final bag first (block 112), which is a user setting.
  • a prescription containing lipids should have the lipids transferred to the final bag first (block 112), which is a user setting.
  • users may wish the lipids to be first or last into the final bag, which is strictly an option that the user can specify.
  • Such specification is preferably based on criteria that is set up initially before the compounder is ever run in a facility.
  • the controller 10 can transfer the fluids utilizing other user settings including settings reflecting the general rules of mixing TPN's (blocks 116, 124).
  • the general rules of mixing total parenteral nutrients include the following:
  • the controller 10 set the order of pumping to insure that the fluid added to the final bag, the primary determination of the order of pumping is the compatibility of the fluid entering the bag with the fluid present in the bag.
  • the number of compatibility groups is also determined, as is the number of rinses required (block 122) and the sequence of transfers and rinses with lipids last is determined using one or more of the compounding methods is executed and the final step shown by line 126 that extends to FIG. 4d results in the transfer instructions being sent to the compounder (block 120).
  • the program determines from the prescription whether lipids are contained in the bag and if so, the entire admixture prescription is checked to determine if lipids are in or will be in the final bag. If they are, then the inquiry is made as to whether the user cares whether there is lipid haze in a following admixture prescription (block 132). This is due to the fact that if any rinse is performed using fluid from the final bag some of the lipids will stay behind in the funnel. These lipids may be transferred to a number of the following bags and in an amount sufficient to produce a visible haze in the solution.
  • the present bag is made with lipids and the next bag does not have lipids and no rinse of surfaces which will come into contact with the contents of both bags occurs, then there is a possibility that the .lipids would haze the next bag, particularly if the prior bag utilizes a rinse from the final bag.
  • the compound will not be prepared at that time but will remain in the queue to be compounded at another time (block 134). If the hospital accepts lipid haze, then a warning is printed by the printer (or by a visual display) indicating that there is a possibility that lipid hazing will exist in the funnel (block 136).
  • the initial step is to initiate the compounding set up (block 108) which requires the converting calculations be carried out that have been described with respect to the high flow only routine (block 104) and line 144 extends to FIG. 4c, where the number of compatibility groups and rinses is determined (block 146). Basically, it is a determination as to whether there will be a problem with the prescription if it is compounded in the way that it is written.
  • the program alerts the user that the prescription cannot be compounded if lipids are last and that a pharmacist check may be required (block 164).
  • the program determines whether lipids can be transferred into the final bag first (block 166), which if not, results in the compound not being prepared (block 168). If the lipids can be transferred first, then line 170 extends to FIG. 3d wherein the number of rinses including the volume of lipids and lipids will be transferred to the final bag first (block 172).
  • the program calculates all solubilities including the volume of lipids and the lipids will be transferred to the final bag last (block 174) (FIG. 4d).
  • the calculation of solubilities not including the volume of lipids (block 174) is done to calculate the calcium phosphate solubility based on possibly less volume than what was included in the original screening. Therefore, for example, if there were 50 milliliters of lipids in a 200 milliliter total volume PN, then the phosphate calcium solubility evaluation would be done on 150 milliliters.
  • the program determines whether the total volume excluding lipids is more than the funnel volume (block 176). If yes, line 178 extends to FIG. 4f where the program determines whether lipids are first (block 180) which if yes, results in the program determining whether the number of rinses of a source rinse of base may be held for a rinse in an acceptable sequence (block 182). If it can, the program breaks into compatibility groups and proceeds with compounding with required rinses coming from the selected source container (block 184) and the instructions are transferred to the compounder (block 186). As described above the steps that are described in blocks 182 and 184, while identified as separate steps in the flow chart, are really in actuality interrelated. This is because the number of rinses is a function of the compatibility groups and the compatibility groups must be determined in order to identify where rinses should occur as described earlier.
  • the completion of the compounding is done using the low-flow module and can be done in the funnel of the low-flow module compounder.
  • the program determines if a source rinse volume of a component solution can be held back for a final rinse (block 188) which if yes, results in holding back when source rinse volume of a base component and all other ingredients are compounded in the funnel and transferred to the final bag and the funnel is then to be rinsed with the reserve base (block 190) with the rinse transferred to the final bag and transfer instructions are sent to the compounder (block 192).
  • the capacity of the funnel is important with regard to the volume that can be held out for doing a complete rinse. For example, if the funnel capacity is 50 milliliters and only 30 milliliters can be held back, then there will not be a full funnel rinse and the decision as to whether this is adequate or not can be made from the user.
  • the method of rinsing will see to have the final rinse originate from a source component such as sterile water, dextrose or amino acids and that intermediate rinses may be made using solution from the final bag with the source rinse of a component volume being held back for the final rinse so that the funnel would be cleaned as much as possible.
  • a source component such as sterile water, dextrose or amino acids
  • the program determines whether any amount of the source rinse volume can be held back for a final rinse (block 194) which if yes, it is done, and all other ingredients are compounded in the funnel and it is rinsed with the reserve base (block 196).
  • the transfer instructions are then sent to the compounder (block 198).
  • the path through the flow chart assuming that the total volume is in excess of the funnel volume results in the determination of whether lipids are first in block 180, which really is not applicable because lipids are not present.
  • the steps 182 and 184 may be carried out with the source rinse being from source container and/or the final bag.
  • the controller will preferably utilize rinsing and compounding sequence which eliminates the need to rinse from the final bag.
  • the program determines if lipids may be transferred last (block 206) which if not, the program inquires whether lipid haze is acceptable (block 208), which if not, results in the compounding not be continued (block 210). If it is acceptable, the program produces a warning about lipid haze (block 212).
  • the program determines whether the number of rinses of the source rinse can be held for a rinse and an acceptable sequence can be carried out with one rinse originating from the final bag (block 214). If it can, then the prescription is analyzed for compatibility groups and compounding will proceed with the rinses occurring at the appropriate times with preferably the next to last rinse being done with the final bag with all others from the source components (block 216). In this manner upon rinsing with the contents of the final bag, the ingredients present in the final bag will be diluted as much as possible while allowing for a final source container rinse. The instructions are transferred to the compounder (block 218).
  • line 220 which extends to FIG. 4g results in the program determining if the number of rinses minus 2 (N-2) times the source component rinse can be held for a rinse in an acceptable sequence with two rinses from the final bag being determined (block 222). If yes, then the compatibility group step is again executed (block 224) and instructions to the compounder are issued (block 226). If no, then another determination is made for the number of rinses minus 3 (N-3) (block 228), with compatibility analysis being done if yes (block 230) and transfer instructions are sent to the compounder (block 232). If no, the determination is made regarding N-4 (block 234).
  • the compatibility analysis is again conducted (block 236) and the instructions are transferred to the compounder (block 238). If the determination is no on line 240, the program then determines if a source rinse can be held for a final rinse (block 242) which if yes, results in the compatibility analysis being carried out once again (block 244) and the compounding instructions being issued (block 246).
  • the program determines if any amount of source solution can be held back to make the required volume excluding lipids below the funnel volume (block 248). If the answer is yes, then that appropriate volume is held back and the ingredients are compounded in the funnel and the held base component is used to rinse the funnel (block 250) and the transfer instructions are issued to the compounder (block 252). If not, the program determines if lipids are in the prescription (block 254), which if not, results in the program compounding with all rinses originating from the final bag (block 256) and the instructions are issued to the compounder (block 258) but if lipids are present, the program determines whether lipid haze is cared about (block 258).
  • a warning is issued (block 260) and if it is, the compound will not be prepared (block 262). After issuing the warning, the compounding proceeds with all rinses from the final bag (block 256) which results in the transfer instructions being sent to the compounder (block 258).
  • the compounder and controller may utilize several methods and adaptations to perform the compounding.
  • the controller 10 may send instructions to a controller included as a part of the compounder 12, 14, 16 or the controller may directly operate the compounder or any combination or similar method.
  • the controller computer 10 is adapted to examine the composition of each prescription admixture that is present in a queue of such prescription admixtures for which instructions are sent to the compounder that is to prepare the admixture. By examining the components of each prescription admixture in the queue to determine those admixtures which contain lipids, for example, those admixtures which do contain lipids can be group together in order so that lipid hazing is not a concern until the last of the lipid containing admixtures is prepared.
  • prescription admixtures residing in queues may be sorted and grouped around common components.
  • other desired groupings of admixtures such as by patient type can be determined in a similar fashion.
  • Such reordering of the prescription admixtures in the queue can have the effect of increasing the throughput due to the needs and requirements of a facility.
  • Another important aspect of the present invention involves the ability of the computer 10 to adjust for a user defined overfill volume by increasing the volume of each of the components that are to be added to the prescription admixture by a predetermined amount to achieve an admixture of equal prescription but a slightly higher volume, and thereby compensate for volume that is required to prime an administrator set or address accuracy concerns when the prescription call for extremely small concentrations of an admixture so that the correct amount of the component in the desired concentration will in fact be delivered to the patient.
  • Yet another important aspect of the present invention involves the capability of the computer 10 to receive a user switchable option, which when activated, enables a diluted higher concentration ingredient to be substituted for a prescribed lower concentration ingredient.
  • a user switchable option which when activated, enables a diluted higher concentration ingredient to be substituted for a prescribed lower concentration ingredient.
  • the controller 10 which may employ one of the methods described above to determine stability during and after compounding.
  • a compounding strategy for overfilling of the final bag 46 may be performed. As described previously, overfilling may be desired to compensate for the amount of admixture, which may not be administered due to the system of administration. For example some portion of the solution may be retained in a final bag even after administration.
  • the desired method of setting the overfill may be particularly configured.
  • the overfill volume may be set in absolute amounts, by a percent or so that the final bag will have a specific desired volume.
  • the method calculates the new amounts of ingredients required to achieve an admixture substantially equivalent to the prescribed admixture but at a slightly greater volume.
  • the controller 10 may check the resulting admixture against various criteria to determine if the resulting admixture may be administered. For example for a fluid restricted patient, an overfill may generate an admixture with an amount of fluid in excess of the allowable amount. An alarm may be generated an error message may be displayed to the user.
  • the controller 10 may adjust or suggest the adjustment of the volume of the admixture to avoid having one or more of the ingredients in an amount less than a predetermined level such as that which corresponds to the minimum accuracy amount suggested for a compounder 12. 14, 16.
  • the amount of a component may be 90% of the minimum suggested amount.
  • the controller may then increase the total volume of the admixture such that the amount of the component reaches the minimum suggested amount and indicate to the user that only of a portion of the resulting admixture is to be administered to the patient.
  • the compounder 12, 14, 16 may communicate to the controller 10 during and after the compounding process. For example, should a sensing device as described in U. S. Patent no. 5,927,349 detect an incorrect source solution flowing through one of the conduits 32 an alarm may be communicated. Similarly, during and after compounding the exact quantities of the ingredients transferred to the final bag 46 may be transmitted to the controller 10.
  • the controller 10 may present cost data to the pharmacist or communicate such data to the hospital computer system 28.
  • the controller 10 may adjust the cost data to reflect the actual cost of providing the admixture.
  • some ingredients may come in containers which can only be accessed once before discarding. Thus if such an ingredient is used in an amount less than that in a container, the controller 10 will indicate the cost of the entire container as opposed to that portion of the ingredient used in the admixture.
  • the present invention employs an extensive analysis of admixture components and utilizes known characteristics of components in a novel fashion to control compounders so that such prescription admixtures can be reliably and safely prepared without violating known rules of preparation, but also in a manner consistent with certain user defined preferences.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Business, Economics & Management (AREA)
  • General Health & Medical Sciences (AREA)
  • Tourism & Hospitality (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Economics (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Animal Behavior & Ethology (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Accessories For Mixers (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
EP00983840A 1999-12-03 2000-12-01 Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures Expired - Lifetime EP1148936B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06075077.5A EP1656988B2 (en) 1999-12-03 2000-12-01 Method and apparatus for controlling the strategy of compounding pharmaceutical admixtures

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16889599P 1999-12-03 1999-12-03
US168895P 1999-12-03
PCT/US2000/032651 WO2001039874A1 (en) 1999-12-03 2000-12-01 Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06075077.5A Division EP1656988B2 (en) 1999-12-03 2000-12-01 Method and apparatus for controlling the strategy of compounding pharmaceutical admixtures

Publications (2)

Publication Number Publication Date
EP1148936A1 EP1148936A1 (en) 2001-10-31
EP1148936B1 true EP1148936B1 (en) 2006-07-12

Family

ID=22613397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00983840A Expired - Lifetime EP1148936B1 (en) 1999-12-03 2000-12-01 Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures

Country Status (14)

Country Link
EP (1) EP1148936B1 (zh)
JP (1) JP2003515439A (zh)
KR (1) KR100682422B1 (zh)
CN (1) CN1338972A (zh)
AT (1) ATE332739T1 (zh)
AU (1) AU768397B2 (zh)
BR (1) BR0008018B1 (zh)
CA (1) CA2360788C (zh)
CO (1) CO5290346A1 (zh)
DE (1) DE60029301T2 (zh)
ES (1) ES2267594T3 (zh)
MX (1) MXPA01007901A (zh)
NZ (1) NZ513159A (zh)
WO (1) WO2001039874A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793723B2 (en) 2016-03-15 2023-10-24 Fresenius Kabi Deutschland Gmbh Installation for producing a medical preparation

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306629A1 (en) * 2001-03-02 2002-09-19 Euro-Celtique, S.A. Method and apparatus for compounding individualized dosage forms
FI20021031A (fi) * 2001-12-28 2003-06-29 Pertti Laehteenmaeki Ravintoautomaatti
US7343224B2 (en) * 2001-12-31 2008-03-11 B. Braun Medical Inc. Pharmaceutical compounding systems and methods and information management system for same
EP2239669B8 (en) * 2001-12-31 2015-12-09 B. Braun Medical, Inc. Pharmaceutical compounding information management system
EP1616550A1 (en) * 2003-04-23 2006-01-18 Yuyama Mfg. Co., Ltd. Medicine management system
TW200533566A (en) * 2004-03-25 2005-10-16 Morohoshi Inc Method of transporting medicaments
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
CN100457070C (zh) * 2006-01-13 2009-02-04 葛晓松 一种液体中药调配方法及调配***
CN101028292B (zh) * 2007-03-31 2012-10-31 蔡诗伟 中药药方配药方法
JP5829608B2 (ja) 2009-07-29 2015-12-09 アイシーユー・メディカル・インコーポレーテッド 流体移行デバイスおよびその使用方法
CN102556561B (zh) * 2010-12-31 2014-06-04 路海英 中药自动化药房的出药***
JP6324652B2 (ja) * 2011-08-26 2018-05-16 株式会社タカゾノテクノロジー 調剤システムおよび調剤装置
JP6307440B2 (ja) 2011-12-22 2018-04-04 アイシーユー・メディカル・インコーポレーテッド 流体移送デバイスおよび使用方法
JP6118962B2 (ja) * 2012-04-24 2017-04-26 株式会社タカゾノテクノロジー 調剤システム
US9076115B2 (en) 2013-01-30 2015-07-07 Carefusion 303, Inc. Component based aggregation of medication orders
US11182728B2 (en) 2013-01-30 2021-11-23 Carefusion 303, Inc. Medication workflow management
US9342484B2 (en) 2013-01-30 2016-05-17 Carefusion 303, Inc. Variable dose dispensing system
MX355774B (es) * 2013-05-23 2018-04-30 Carefusion 303 Inc Agregacion basada en componentes de ordenes de medicamentos.
JP6259113B2 (ja) 2013-11-25 2018-01-10 アイシーユー・メディカル・インコーポレーテッド 点滴バッグに治療用流体を充填するための方法およびシステム
WO2016191210A2 (en) 2015-05-22 2016-12-01 B. Braun Medical Inc. Compounding device, system, kit, software and method
WO2016196810A1 (en) 2015-06-04 2016-12-08 B. Braun Medical Inc. Compounding device, system, kit, software, and method
CA3233913A1 (en) 2015-12-04 2017-06-08 Icu Medical, Inc. Systems, methods, and components for transferring medical fluids
FR3046360B1 (fr) * 2016-01-05 2018-02-16 Ac&B Procede et dispositif avec interface pour la fabrication d'un produit personnalise
USD851745S1 (en) 2016-07-19 2019-06-18 Icu Medical, Inc. Medical fluid transfer system
AU2017302557B2 (en) 2016-07-25 2022-10-13 Icu Medical, Inc. Systems, methods, and components for trapping air bubbles in medical fluid transfer modules and systems
CN110662523B (zh) 2017-03-24 2021-11-23 康尔福盛303公司 用于自动药剂复配机的注射器泵
JP7486422B2 (ja) 2017-12-29 2024-05-17 ロレアル 個別の化粧品組成物を実現するための装置及び方法
CN108257652B (zh) * 2018-01-15 2022-02-25 合肥市第一人民医院 一种输液顺序智能提醒调控***
US11590057B2 (en) 2020-04-03 2023-02-28 Icu Medical, Inc. Systems, methods, and components for transferring medical fluids
CN111557818B (zh) * 2020-05-27 2021-08-20 上海然芯信息科技有限公司 一种基于5g设备的多种功能医疗装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2681099B2 (ja) * 1986-12-05 1997-11-19 クリンテック、ニュートリション、カンパニー 単一容器へ多数の流体を加えるための自動化システム
US5228485A (en) * 1986-12-08 1993-07-20 Clintec Nutrition Co. Flexible tubing occlusion sensor
US5085256A (en) * 1990-03-29 1992-02-04 Clintec Nutrition Co. Drift stabilization check
US5208762A (en) * 1990-12-06 1993-05-04 Baxter International Inc. Automated prescription vial filling system
SE504683C2 (sv) * 1995-05-03 1997-04-07 Astra Ab Anordning för att blanda en farmaceutisk komposition med ett annat medel
JPH09225008A (ja) * 1996-02-26 1997-09-02 Nikka Micron Kk 薬液調合装置
US5927349A (en) * 1996-12-09 1999-07-27 Baxter International Inc. Compounding assembly for nutritional fluids
JP4122107B2 (ja) * 1999-04-27 2008-07-23 株式会社湯山製作所 注射剤混合支援装置
SE9901736D0 (sv) * 1999-05-12 1999-05-12 Pharmacia & Upjohn Ab Injectino device and method for ITS operation
JP4141097B2 (ja) * 2000-10-06 2008-08-27 株式会社トーショー 薬袋印刷装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793723B2 (en) 2016-03-15 2023-10-24 Fresenius Kabi Deutschland Gmbh Installation for producing a medical preparation

Also Published As

Publication number Publication date
DE60029301D1 (de) 2006-08-24
MXPA01007901A (es) 2002-04-24
CA2360788C (en) 2009-04-14
AU768397B2 (en) 2003-12-11
BR0008018A (pt) 2001-11-06
CN1338972A (zh) 2002-03-06
KR20010101928A (ko) 2001-11-15
CO5290346A1 (es) 2003-06-27
ATE332739T1 (de) 2006-08-15
BR0008018B1 (pt) 2010-07-27
AU2055001A (en) 2001-06-12
CA2360788A1 (en) 2001-06-07
WO2001039874A1 (en) 2001-06-07
DE60029301T2 (de) 2007-07-05
JP2003515439A (ja) 2003-05-07
EP1148936A1 (en) 2001-10-31
NZ513159A (en) 2002-10-25
ES2267594T3 (es) 2007-03-16
KR100682422B1 (ko) 2007-02-15

Similar Documents

Publication Publication Date Title
US6975924B2 (en) Method and apparatus for controlling the strategy of compounding pharmaceutical admixtures
EP1148936B1 (en) Method and apapratus for controlling the strategy of compounding pharmaceutical admixtures
US9668940B2 (en) Systems and methods for compounding a preparation using a premix solution
US5925014A (en) Method and apparatus for preparing and administering intravenous anesthesia infusions
EP1836663B1 (en) Apparatus and method for transferring data to a pharmaceutical compounding system
EP1689362B1 (en) Pharmaceutical compounding systems and methods and information management system for same
EP1656988B1 (en) Method and apparatus for controlling the strategy of compounding pharmaceutical admixtures
WO1993010851A1 (en) Method, apparatus for preparing and administering intravenous anesthesia infusions
Kastango Using ACDs in the practice of pharmacy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040428

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEWIS, ROBERT, E.

Inventor name: NITZKI-GEORGE, DIANE, M.

Inventor name: CZARNY, RONALD, W.

Inventor name: KIRCHER, JOSEPH, J.

Inventor name: MILLER, JOSEPH, E.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAXTER INTERNATIONAL INC.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60029301

Country of ref document: DE

Date of ref document: 20060824

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061012

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2267594

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060712

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20091123

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20101229

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20101227

Year of fee payment: 11

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111202

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20161228

Year of fee payment: 17

Ref country code: IE

Payment date: 20161229

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20161227

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20161229

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20161222

Year of fee payment: 17

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20170710

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60029301

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20171201

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180102

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180703

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171201